Stryker Corporation

New York Stock Exchange
Back to all articles
Neutral 0

Stryker to participate in the Bank of America Securities 2026 Global Healthcare Conference

📅 Stryker (NYSE: SYK) will host a presentation at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026.

📍 The event will take place at the Encore at Wynn Hotel in Las Vegas, Nevada, with Stryker's session scheduled for 1:40 p.m. Pacific Time.

👥 Spencer Stiles (President and COO), Jason Beach (VP and Group CFO), and Nick Mead (VP of Investor Relations) will represent Stryker at the conference.

🌐 The company's live webcast and a replay of the presentation will be available on its investor relations website after the event.

🏥 Stryker is a global leader in medical technologies with offerings in MedSurg, Neurotechnology, and Orthopaedics that serve over 150 million patients annually.

💰 Recent analyst actions show conflicting price targets, with Goldman Sachs raising their target to $361 while Baird and Bernstein have lowered theirs.

📉 Some analysts note recent quarterly challenges, including a sales miss in Q1 attributed to cyber disruption issues.

🏆 TD Cowen maintains a Hold rating on Stryker stock, indicating steady but cautious market sentiment among financial advisors.

🔗 Contact information for Nick Mead and Kim Montagnino is provided in the press release for investor inquiries regarding the conference.

⚠️ The company warns of potential future risks related to cybersecurity that impacted recent earnings performance.

Bullish Signals
  • Stryker is a global leader in medical technologies that impacts more than 150 million patients annually through its innovative products and services.
  • The company will present at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, providing an opportunity to discuss future growth with major stakeholders.
  • Key executives Spencer Stiles, Jason Beach, and Nick Mead will attend to highlight Stryker's strong leadership in MedSurg, Neurotechnology, and Orthopaedics.
Risk Factors
  • Stryker recently missed Q1 earnings and sales estimates due to cyber disruption, indicating operational vulnerabilities.
  • Multiple major investment banks have recently lowered their price targets for Stryker: Baird cut its target from $465 to $410, while Bernstein reduced theirs from $465 to $410.
  • Analyst sentiment is conflicted and negative, with a concurrent report noting analyst conflicts on Moderna and Stryker.
  • Despite one analyst (Goldman Sachs) raising their target to $361, two others (Baird and Bernstein) lowered targets from over $465 to the high $300s within just one day.
Full Analysis
The article announces that Stryker (NYSE: SYK), a global leader in medical technologies with products in MedSurg, Neurotechnology, and Orthopaedics, will participate in the Bank of America Securities 2026 Global Healthcare Conference. The event is scheduled for Wednesday, May 13, 2026, at the Encore at Wynn Hotel in Las Vegas, Nevada. A company presentation is set to occur at 1:40 p.m. Pacific Time, featuring Spencer Stiles, President and Chief Operating Officer; Jason Beach, Vice President and Group Chief Financial Officer for MedSurg and Neurotechnology; and Nick Mead, Vice President of Investor Relations. Viewers can access a live webcast and a subsequent replay through Stryker's investor relations website. Stryker describes itself as being driven to make healthcare better alongside its customers, offering innovative products that improve patient and healthcare outcomes. The company states it impacts more than 150 million patients annually with its offerings worldwide. Contact information is provided for Nick Mead at 269-385-2600 or nick.mead@stryker.com, and for Kim Montagnino, Vice President of Chief Communications Officer, at the same number or kim.montagnino@stryker.com. The news release is contextualized by a series of recent market updates regarding Stryker's stock price targets and analyst ratings found in the appended text from TipRanks and other sources. Over the past 24 hours, Goldman Sachs raised its price target to $361 from $357, while Baird lowered its target to $385 from $437. Similarly, Bernstein reduced its target to $410 from $465. Despite some conflicting analyst opinions highlighted in the source text regarding Moderna and Stryker, TD Cowen maintains a Hold rating on Stryker. The company also recently reported that its Q1 earnings and sales missed estimates due to cyber disruption, as noted in accompanying headlines.